BRVE insider filings

Braveheart Bio, Inc. — 14 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-11. Screen BRVE transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for BRVE between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Braveheart Bio, Inc.

FiledFormInsiderReported transactionsSource
2026-08-114AH Bio Fund IV, L.P. — 10% owner
AH Equity Partners Bio IV, L.L.C. — 10% owner
Andreessen Marc L — 10% owner
HOROWITZ BENJAMIN A — 10% owner
Conversion (C): 9,132,420 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0EDGAR
2026-08-114Chimovits Erez — Director, 10% ownerConversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0EDGAR
2026-08-114ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP IX LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0EDGAR
2026-08-104Jiangsu Hengrui Pharmaceuticals Co., Ltd. — 10% ownerConversion (C): 7,420,091 · Conversion (C): 32,500,000 (derivative) @ $0EDGAR
2026-08-074Forbion Growth Opportunities Fund III Cooperatief U.A. — 10% owner
Forbion Growth III Management B.V. — 10% owner
Forbion Ventures Fund VII Cooperatief U.A. — 10% owner
Forbion Ventures VII Management B.V. — 10% owner
Conversion (C): 9,132,420 @ $0 · Conversion (C): 7,990,867 @ $0 · Purchase (P): 1,920,000 @ $18 · Purchase (P): 1,680,000 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 · Conversion (C): 35,000,000 (derivative) @ $0EDGAR
2026-08-074Lohoff Tim — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-08-074Rickey James Paul — Chief Financial OfficerPurchase (P): 27,777 @ $18 · Grant/award (A): 300,000 (derivative) @ $0EDGAR
2026-08-074Lubner David Charles — DirectorPurchase (P): 55,555 @ $18 · Grant/award (A): 60,000 (derivative) @ $0EDGAR
2026-08-074Bos Jasper — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2026-08-074Murdoch Travis — CEO and President, DirectorPurchase (P): 83,333 @ $18 · Grant/award (A): 550,000 (derivative) @ $0EDGAR
2026-08-074Anderson Michele A. — Chief Development OfficerPurchase (P): 1,111 @ $18 · Grant/award (A): 300,000 (derivative) @ $0EDGAR
2026-08-074Malek David I — DirectorPurchase (P): 4,166 @ $18 · Grant/award (A): 30,000 (derivative) @ $0EDGAR
2026-08-074Viehbacher Christopher — DirectorPurchase (P): 83,333 @ $18 · Grant/award (A): 30,000 (derivative) @ $0EDGAR
2026-08-074Chimovits Erez — Director, 10% ownerGrant/award (A): 30,000 (derivative) @ $0EDGAR

Recent 8-K events — Braveheart Bio, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-068-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-078-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — Braveheart Bio, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BRVE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs